BLUDIGO Drug Patent Profile
✉ Email this page to a colleague
When do Bludigo patents expire, and what generic alternatives are available?
Bludigo is a drug marketed by Provepharm Sas and is included in one NDA. There are three patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in BLUDIGO is indigotindisulfonate sodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indigotindisulfonate sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Bludigo
Bludigo will be eligible for patent challenges on July 8, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 23, 2037. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BLUDIGO?
- What are the global sales for BLUDIGO?
- What is Average Wholesale Price for BLUDIGO?
Summary for BLUDIGO
International Patents: | 2 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 109 |
Clinical Trials: | 2 |
Patent Applications: | 4,114 |
Drug Prices: | Drug price information for BLUDIGO |
What excipients (inactive ingredients) are in BLUDIGO? | BLUDIGO excipients list |
DailyMed Link: | BLUDIGO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BLUDIGO
Generic Entry Date for BLUDIGO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for BLUDIGO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Prove pharm | Phase 4 |
Pharmacology for BLUDIGO
Drug Class | Diagnostic Dye |
Mechanism of Action | Dyes |
US Patents and Regulatory Information for BLUDIGO
BLUDIGO is protected by three US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of BLUDIGO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting BLUDIGO
Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting BLUDIGO
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BLUDIGO
When does loss-of-exclusivity occur for BLUDIGO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
European Patent Office
Patent: 59121
Patent: NOUVEAU PROCÉDÉ POUR LA PRÉPARATION D'INDIGOTINDISULFONATE DE SODIUM (CARMIN D'INDIGO) (NOVEL PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE))
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering BLUDIGO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2018116325 | ⤷ Sign Up | |
European Patent Office | 3559121 | NOUVEAU PROCÉDÉ POUR LA PRÉPARATION D'INDIGOTINDISULFONATE DE SODIUM (CARMIN D'INDIGO) (NOVEL PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE)) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |